Optimizing Integration of Precision Therapy Into the Treatment of HER2-Low, HR-Positive, and Triple Negative Breast Cancer: A Focus on HER2 Targeted and TROP-2–Targeted Therapy

Activity

Progress
1
Course Completed
Activity Information

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 20, 2023

Expiration: June 19, 2024

Aditya Bardia
Aditya Bardia, MD, MPH, FASCO
Sara A. Hurvitz
Sara A. Hurvitz, MD, FACP
Shanu Modi
Shanu Modi, MD